The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia

Acute ischemic stroke is the leading cause of morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only agent clinically approved by FDA for patients with acute ischemic stroke. However, delayed treatment of rtPA (e.g., more than 3 h after stroke onset) exacerbat...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Hwa Young, Chung, Jee-In, Jalin, Angela Melinda Anthony, Ju, Chung, Pahk, Kisoo, Joung, Chanmin, Lee, Sekwang, Jin, Sejong, Kim, Byoung Soo, Lee, Ki Sung, Ryu, Jei-Man, Kim, Won-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835804/
https://www.ncbi.nlm.nih.gov/pubmed/35163322
http://dx.doi.org/10.3390/ijms23031403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835804/
https://www.ncbi.nlm.nih.gov/pubmed/35163322
http://dx.doi.org/10.3390/ijms23031403

Ejemplares similares